Deepika Pakianathan

CIK: 0001270734

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

TBPH

Theravance Biopharma, Inc.

Director

FRNM

Freenome, Inc.

Director

KPTI

Karyopharm Therapeutics Inc.

Director

MREO

Mereo BioPharma Group plc

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TBPH
Theravance Biopharma, Inc.
Sep 23, 2026
Disposition(D)
Direct
58.1K shares-
TBPH
Theravance Biopharma, Inc.
Sep 23, 2026
Disposition(D)
Direct
6K shares-
TBPH
Theravance Biopharma, Inc.
Jun 12, 2026
Award(A)
Direct
6K shares-
KPTI
Karyopharm Therapeutics Inc.
May 21, 2026
Award(A)
Direct
15.5K shares-
MREO
Mereo BioPharma Group plc
Feb 26, 2026
Award(A)
Share Options (Right to buy)
Direct
66K shares-
KPTI
Karyopharm Therapeutics Inc.
May 28, 2025
Award(A)
Nonstatutory Stock Option (right to buy)
Direct
4.6K shares-
TBPH
Theravance Biopharma, Inc.
May 19, 2025
Award(A)
Direct
10.6K shares-
MREO
Mereo BioPharma Group plc
Feb 5, 2025
Award(A)
Share Options (Right to buy)
Direct
55K shares-

		Type	Shares	Price		Ownership
Sep 23, 2026	TBPH Theravance Biopharma, Inc.	Disposition(D)	58,065	-	$0	Direct
Sep 23, 2026	TBPH Theravance Biopharma, Inc.	Disposition(D)	6,009	-	$0	Direct
Jun 12, 2026	TBPH Theravance Biopharma, Inc.	Award(A)	6,009	-	$0	Direct
May 21, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	15,508	-	$0	Direct
Feb 26, 2026	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	66,000	-	-	Direct
May 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A) Nonstatutory Stock Option (right to buy)	4,600	-	-	Direct
May 19, 2025	TBPH Theravance Biopharma, Inc.	Award(A)	10,649	-	-	Direct
Feb 5, 2025	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	55,000	-	-	Direct

1-8 of 8 transactions

About PAKIANATHAN DEEPIKA

PAKIANATHAN DEEPIKA (SEC CIK 0001270734) files insider reports with the SEC as Director of Theravance Biopharma, Inc. (TBPH), Director of Freenome, Inc. (FRNM) and Director of Karyopharm Therapeutics Inc. (KPTI). Signal8 also holds filings tied to 1 other company.

Signal8 holds 8 ownership filings by PAKIANATHAN DEEPIKA (1 Form 3, 7 Form 4), filed between Feb 6, 2025 and Sep 24, 2026. Those filings report 8 transactions, from Feb 5, 2025 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PAKIANATHAN DEEPIKA's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by PAKIANATHAN DEEPIKA

Sep 23, 2026: Disposition to issuer transactions of TBPH shares (2 lines, Form 4, code D).
Jun 12, 2026: Grant or award of TBPH shares (Form 4, code A).
May 21, 2026: Grant or award of KPTI shares (Form 4, code A).
Feb 26, 2026: Grant or award of MREO derivative securities (Form 4, code A).
May 28, 2025: Grant or award of KPTI derivative securities (Form 4, code A).

Other insiders filing for Theravance Biopharma, Inc. (TBPH)

Weiss Asset Management LP, Officer
O'Connor Donal, Director
MITCHELL DEAN J, Director
GRAY SUSANNAH, Director
Smaldone Alsup Laurie, Director
Winningham Rick E, CHIEF EXECUTIVE OFFICER

How to read Form 4 transaction codes